Journal of Hepatology10.1016/s0168-8278(05)81882-3200542170470 HBeAg negative patients with chronic hepatitis B are less likely to have A biochemical breakthrough during lamivudine treatment,
Journal of Hepatology10.1016/s0168-8278(05)81916-6200542182504 Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B,
Journal of Hepatology10.1016/s0168-8278(05)81922-1200542185510 HBsAg levels under interferon and lamivudine therapy in HBeAg-negative chronic hepatitis B (CHBe-) patients,
Intervirology10.1159/0000749902003466344-349Viral Breakthrough during Lamivudine Therapy for Chronic Hepatitis BNancy Leung,
Hepatology10.1016/s0270-9139(03)81216-8200338723-7231178 Effect of the precore mutations on the HBEAG loss and viral breakthrough during lamivudine therapy in HBEAG-positive chronic hepatitis BS KIM, Y HWANG, K KWON, M JUNG, D PARK, O KWON, S KWON, Y KIM, Y KOO, Y KIM,
Journal of Viral Hepatitis10.1111/j.1365-2893.2011.01542.x2011193220-226Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patientsR. Idilman, K. Cinar, G. Seven, Y. Bozkus, A. Elhan, M. Bozdayi, C. Yurdaydin, K. Bahar,
Yearbook of Gastroenterology10.1016/s0739-5930(08)70202-220072007253-255Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BG.A. Makar,
Yearbook of Pediatrics10.1016/s0084-3954(08)70153-220072007276-278Entecavir Versus Lamivudine for Patients With HBeAg-Negative Chronic Hepatitis BJ.A. Stockman,
Yearbook of Medicine10.1016/s0084-3873(08)70051-82007200780-81Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BD.R. Snydman,
Hepatology10.1053/jhep.2001.272202001343583-589Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequencesC Liu,